The small-molecule inhibitor of mutant IDH1, Ivosidenib (AG-120), has been FDA-approved for the treatment of adult relapsed or refractory AML with IDH1 mutations on 20 July 2018 [198]. The gene discussed is IDH1; the disease is acute myeloid leukemia.